| Zhao, Kuaile |
NCT06190782: Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor |
|
|
| Recruiting | 3 | 354 | RoW | PD-1 inhibitor+/- chemotherapy combined with local therapy, systemic therapy alone, the systemic therapy only | Fudan University | Esophageal Squamous Cell Carcinoma, Oligometastatic Disease, Radiotherapy | 09/25 | 09/27 | | |
NCT03790553: Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma |
|
|
| Recruiting | 3 | 646 | RoW | Radiotherapy | Fudan University | Esophageal Squamous Cell Carcinoma | 10/23 | 10/25 | | |
NCT04519905: Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15) |
|
|
| Recruiting | 3 | 320 | RoW | Paclitaxel plus carboplatin, radiotherapy | Fudan University, Huadong Hospital, Jiangsu Cancer Institute & Hospital, Gansu Cancer Hospital, The First Affiliated Hospital of Xiamen University, Fujian Cancer Hospital, Taihe Hospital, Wuxi No. 4 People's Hospital, Ningbo No.2 Hospital | Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Survival | 12/24 | 12/27 | | |
NCT05425472: A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer |
|
|
| Recruiting | 2 | 30 | RoW | HR070803 | Jiangsu HengRui Medicine Co., Ltd. | Advanced Esophageal Cancer | 01/23 | 03/23 | | |
NCT04764227: Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) |
|
|
| Active, not recruiting | 2 | 70 | RoW | Paclitaxel, Carboplatin, Radiotherapy | Fudan University | Esophagus Cancer, Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Radiation Therapy, Postoperative | 03/24 | 03/27 | | |
NCT05131763: NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors |
|
|
| Recruiting | 1 | 3 | RoW | NKG2D-based CAR T-cells | Fudan University, KAEDI | Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon Cancer | 12/22 | 12/23 | | |
NCT04694391: Genomic Study of Relapse Esophageal Cancer After Radiotherapy |
|
|
| Recruiting | N/A | 200 | RoW | whole exome sequence | Fudan University, M.D. Anderson Cancer Center, Nantong University, Jiangsu Cancer Institute & Hospital, Henan Cancer Hospital, Ningbo No.2 Hospital, Taihe Hospital, Taian Cancer Hospital | Gene Mutation-Related Cancer, Esophageal Cancer, Radiation Exposure | 12/20 | 12/22 | | |
NCT06393140: The Study on the Mechanism of Radiotherapy-elicited Immune Response |
|
|
| Recruiting | N/A | 200 | RoW | | Fudan University | Esophageal Carcinoma Salivary Gland Type, Radiotherapy | 07/26 | 07/26 | | |
NCT05142709: Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC. |
|
|
| Active, not recruiting | N/A | 600 | RoW | Anti-PD-1 Immune Checkpoint Inhibitors | Fudan University | Metastatic Esophageal Squamous Cell Carcinoma | 09/23 | 12/24 | | |
| Recruiting | N/A | 50 | RoW | Cola | Fudan University | Esophageal Cancer | 10/25 | 06/26 | | |
NCT05760391: A Study of IO Plus Radiotherapy in Patients With Advanced ESCC. |
|
|
| Recruiting | N/A | 100 | RoW | Radiotherapy | Fudan University | Metastatic Esophageal Squamous Cell Carcinoma | 02/25 | 08/26 | | |
NCT05426850: ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma |
|
|
| Recruiting | N/A | 100 | RoW | | Fudan University | Esophageal Squamous Cell Carcinoma | 12/22 | 12/24 | | |
| Cai, Changchun |
NCT05131763: NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors |
|
|
| Recruiting | 1 | 3 | RoW | NKG2D-based CAR T-cells | Fudan University, KAEDI | Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma, Colon Cancer | 12/22 | 12/23 | | |
